Download DNB 2019 Dec 2019 Dec MEDICAL ONCOLOGY PAPER I Question Paper

FirstRanker.com

FINAL EXAM

DECEMBER 2019

--- Content provided by‌ FirstRanker.com ---

Time: 3 hours

MEDICAL ONCOLOGY

PAPER-I

Max. Marks: 100

Important Instructions:

--- Content provided by⁠ FirstRanker.com ---

• Attempt all questions in order.
• Each question carries 10 marks.
• Read the question carefully and answer to the point neatly and legibly.
• Do not leave any blank pages between two answers.
• Indicate the question number correctly for the answer in the margin space.

--- Content provided by​ FirstRanker.com ---

• Answer all the parts of a single question together.
• Start the answer to a question on a fresh page or leave adequate space between two answers.
• Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:

1. a) Clonal evolution theory. (3+4+3)
   

   --- Content provided by‌ FirstRanker.com ---

   b) Cancer stem cell theory.
   c) Tumour heterogeneity.
2. a) Enumerate the common carcinogens in tobacco. (2+3+5)
   b) Which are the common cancers caused by tobacco?
   c) Describe in detail carcinogenesis due to tobacco.

--- Content provided by‍ FirstRanker.com ---

3. a) Radiosensitizer. (2+3+2+3)
   b) Fractionation of radiation therapy and its importance.
   c) Image guided radiation therapy (IGRT).
   d) Gamma knife.
4. a) Scientific rationale and scope of liquid biopsy in cancer. (3+4+3)
   

   --- Content provided by FirstRanker.com ---

   b) Clinical application of liquid biopsy in management of solid tumours.
   c) Potential limitation of liquid biopsy.
5. a) What is cancer genetic counselling? (2+2+3+3)
   b) Enumerate the hereditary cancer syndromes.
   c) How do you counsel a 23-year old lady whose mother and elder sister died of breast cancer?
   

   --- Content provided by FirstRanker.com ---

   d) Management of BRCA carrier.
6. a) Phases of cancer drug clinical trials. (3+4+3)
   b) Importance of informed consent in clinical trials.
   c) Role of principal investigator in clinical trials.
7. a) Define oligometastatic disease. (2+4+4)
   

   --- Content provided by‍ FirstRanker.com ---

   b) Role of circulating tumour cells as a predictor of metastatic disease.
   c) Management of oligometastatic breast cancer.
8. a) What is molecular tumour marker? (2+4+4)
   b) Molecular tumour board.
   c) Predictive biomarkers for checkpoint inhibitor-based immunotherapy.

--- Content provided by FirstRanker.com ---

9. a) Survival analysis in cancer. (3+2+3+2)
   b) p-value.
   c) Forest plot and its interpretation.
   d) Meta-analysis.
10. a) Kinases and cancer. (2+4+4)
    

    --- Content provided by​ FirstRanker.com ---

    b) Kinase amplifications as diagnostic molecular marker in cancer.
    c) Kinase targeted therapy in various cancers.

FirstRanker.com